lunedì, 18 ottobre 2021
17 Marzo 2017

FDA Approves Ribociclib for Frontline HR+/HER2- Breast Cancer

March 13, 2017 – The FDA has approved the CDK 4/6 inhibitor ribociclib for use in combination with an aromatase inhibitor for the frontline treatment of postmenopausal women with hormone-receptor (HR)–positive, HER2-negative advanced breast cancer. The approval is based on findings from the phase III MONALEESA-2 trial, in which combining ribociclib with letrozole reduced the risk of progression or death by 44% compared with letrozole alone in the … (leggi tutto)